Published in Nat Genet on January 06, 2013
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol (2013) 2.60
Type I interferons in infectious disease. Nat Rev Immunol (2015) 2.37
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med (2013) 2.24
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis (2014) 2.06
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 2.02
Hepatitis C. Lancet (2015) 1.95
Regulation of hepatic innate immunity by hepatitis C virus. Nat Med (2013) 1.93
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. J Exp Med (2014) 1.61
Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology (2014) 1.46
Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov (2013) 1.43
IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet (2017) 1.41
Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J (2013) 1.40
IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis (2013) 1.39
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol (2013) 1.35
IFN-λ4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res (2014) 1.32
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest (2014) 1.29
Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol (2015) 1.22
Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology (2015) 1.19
Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe (2014) 1.19
Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. J Infect Dis (2013) 1.18
The genetic theory of infectious diseases: a brief history and selected illustrations. Annu Rev Genomics Hum Genet (2013) 1.17
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond. Immunity (2015) 1.16
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun (2015) 1.14
HIV-1 and interferons: who's interfering with whom? Nat Rev Microbiol (2015) 1.14
NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci U S A (2015) 1.14
Guarding the frontiers: the biology of type III interferons. Nat Immunol (2015) 1.12
Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest (2013) 1.12
Emerging therapies for the treatment of hepatitis C. EMBO Mol Med (2014) 1.09
Population genetic tools for dissecting innate immunity in humans. Nat Rev Immunol (2013) 1.08
Deep sequencing: becoming a critical tool in clinical virology. J Clin Virol (2014) 1.07
Interferon-λ4 (IFNL4) transcript expression in human liver tissue samples. PLoS One (2013) 1.07
Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun (2014) 1.01
HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hepatology (2014) 0.99
Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol (2015) 0.99
Sustained Virologic Response for Chronic Hepatitis C Infection after 27 Days of Treatment with Sofosbuvir and Ribavirin. Open Forum Infect Dis (2014) 0.97
Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol (2013) 0.96
The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect (2014) 0.96
Immunologic, metabolic and genetic factors in hepatitis C virus infection. World J Gastroenterol (2014) 0.96
Targeted induction of interferon-λ in humanized chimeric mouse liver abrogates hepatotropic virus infection. PLoS One (2013) 0.95
The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing. J Hepatol (2014) 0.94
Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 0.94
Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet (2014) 0.92
Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol (2013) 0.91
Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol (2014) 0.91
Murine models of hepatitis C: what can we look forward to? Antiviral Res (2014) 0.90
The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon (2014) 0.90
Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden. Virology (2015) 0.89
Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS One (2014) 0.89
Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C. Nat Genet (2013) 0.89
Human but not mouse hepatocytes respond to interferon-lambda in vivo. PLoS One (2014) 0.88
Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men. Clin Infect Dis (2015) 0.88
Dynamics of HCV RNA levels during acute hepatitis C virus infection. J Med Virol (2014) 0.87
Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87
Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol (2013) 0.87
Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study. Genes Immun (2015) 0.86
Expression of Interferon Lambda 4 Is Associated with Reduced Proliferation and Increased Cell Death in Human Hepatic Cells. J Interferon Cytokine Res (2015) 0.86
The IFN-λ Genetic Polymorphism Association With the Viral Clearance Induced by Hepatitis C Virus Treatment in Pakistani Patients. Hepat Mon (2014) 0.86
Transcriptome analysis reveals a classical interferon signature induced by IFNλ4 in human primary cells. Genes Immun (2015) 0.86
Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol (2016) 0.86
Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism. PLoS One (2013) 0.85
Differences in hepatitis C virus prevalence and clearance by mode of acquisition among men who have sex with men. J Viral Hepat (2013) 0.85
Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Front Immunol (2014) 0.85
IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians. PLoS One (2014) 0.85
Interferon induction by RNA viruses and antagonism by viral pathogens. Viruses (2014) 0.84
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses (2015) 0.84
Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol (2014) 0.84
Lipopolysaccharide and Tumor Necrosis Factor Alpha Inhibit Interferon Signaling in Hepatocytes by Increasing Ubiquitin-Like Protease 18 (USP18) Expression. J Virol (2016) 0.83
Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C. Clin Exp Med (2016) 0.83
Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. Biomed Res Int (2014) 0.83
Monitoring the immune response to vaccination with an inactivated vaccine associated to bovine neonatal pancytopenia by deep sequencing transcriptome analysis in cattle. Vet Res (2013) 0.83
The unique regulation and functions of type III interferons in antiviral immunity. Curr Opin Virol (2015) 0.83
IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. Int J Hepatol (2014) 0.83
Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int (2013) 0.82
Impact and regulation of lambda interferon response in human metapneumovirus infection. J Virol (2014) 0.82
A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-κB-mediated gene transcription. PLoS One (2013) 0.82
HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study. PLoS One (2013) 0.82
Post-transcriptional regulation of interferons and their signaling pathways. J Interferon Cytokine Res (2014) 0.82
T cell responses in hepatitis C virus infection: historical overview and goals for future research. Antiviral Res (2014) 0.82
IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep (2015) 0.82
Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. J Viral Hepat (2015) 0.82
The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era. Can J Gastroenterol Hepatol (2014) 0.82
Transmission of hepatitis C virus: self-limiting hepatitis or chronic hepatitis? World J Gastroenterol (2013) 0.81
The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA. Nat Rev Microbiol (2015) 0.81
Hepatitis C Virus. Strategies to Evade Antiviral Responses. Future Virol (2015) 0.81
Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection. PLoS One (2013) 0.81
The bacterial pathogen Listeria monocytogenes and the interferon family: type I, type II and type III interferons. Front Cell Infect Microbiol (2014) 0.80
Hepatitis: New gene IFNL4 is associated with impaired clearance of HCV. Nat Rev Gastroenterol Hepatol (2013) 0.80
IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. Immunogenetics (2013) 0.80
KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan. PLoS One (2013) 0.80
Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV. Front Immunol (2014) 0.80
Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection. Liver Int (2015) 0.80
Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. Curr Opin Virol (2016) 0.79
Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat (2016) 0.79
Interferon lambda inhibits dengue virus replication in epithelial cells. Virol J (2015) 0.79
Interferon-lambda polymorphisms and hepatitis C virus clearance revisited. Hepatology (2013) 0.79
Activation of Type I and III Interferon Response by Mitochondrial and Peroxisomal MAVS and Inhibition by Hepatitis C Virus. PLoS Pathog (2015) 0.79
Single cell analysis of HCV-infected patient hepatocytes: the science is no longer science fiction. Gastroenterology (2013) 0.79
A map of human genome variation from population-scale sequencing. Nature (2010) 121.13
The International HapMap Project. Nature (2003) 73.65
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
CTCF: master weaver of the genome. Cell (2009) 15.09
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87
IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A (2008) 8.56
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr (1991) 7.05
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Lambda interferon inhibits hepatitis B and C virus replication. J Virol (2005) 5.47
NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements (2004) 5.19
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
ENCODE whole-genome data in the UCSC Genome Browser: update 2012. Nucleic Acids Res (2011) 4.00
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Messenger RNA regulation: to translate or to degrade. EMBO J (2008) 3.38
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology (2012) 3.12
Continuous c-fos expression precedes programmed cell death in vivo. Nature (1993) 2.85
Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology (2010) 2.68
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology (2011) 2.13
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 2.02
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology (2012) 1.96
National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology (2002) 1.91
Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem (2009) 1.73
Structure and mechanism of receptor sharing by the IL-10R2 common chain. Structure (2010) 1.63
Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc Natl Acad Sci U S A (1999) 1.50
Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol (2011) 1.47
2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int (2012) 1.47
Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol (2011) 1.45
Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology (2008) 1.40
Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex. J Biol Chem (2006) 1.31
HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology (2012) 1.30
Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology (2011) 1.28
Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology (2011) 1.19
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med (2011) 1.19
Frequent appearance of novel protein-coding sequences by frameshift translation. Genomics (2006) 1.14
IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. J Infect Dis (2011) 1.07
Adjuvant therapy for melanoma. Cancer J (2012) 1.01
Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. PLoS One (2011) 0.98
Structure and function of interleukin-22 and other members of the interleukin-10 family. Cell Mol Life Sci (2010) 0.97
Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities. Int J Immunopathol Pharmacol (2004) 0.95
The evolution of proteins from random amino acid sequences: II. Evidence from the statistical distributions of the lengths of modern protein sequences. J Mol Evol (1994) 0.92
c-Fos regulates hepatitis C virus propagation. FEBS Lett (2011) 0.91
CCL5: a double-edged sword in host defense against the hepatitis C virus. Int Rev Immunol (2011) 0.91
Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon. Ital J Gastroenterol Hepatol (1997) 0.88
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature (2010) 12.07
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol (2009) 9.43
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
Prediction error estimation: a comparison of resampling methods. Bioinformatics (2005) 6.41
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
On criteria for evaluating models of absolute risk. Biostatistics (2005) 5.71
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Alcoholic hepatitis. N Engl J Med (2009) 4.98
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med (2011) 4.81
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Pathway analysis by adaptive combination of P-values. Genet Epidemiol (2009) 4.48
Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol (2004) 4.45
Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med (2010) 4.30
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer (2003) 4.02
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
The liver as an immunological organ. Hepatology (2006) 3.86
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst (2005) 3.75
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res (2005) 3.33
Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell (2013) 3.30
The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2011) 3.29
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Top-down control of human visual cortex by frontal and parietal cortex in anticipatory visual spatial attention. J Neurosci (2008) 3.07
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res (2009) 2.86
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol (2004) 2.81
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2004) 2.67
Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology (2004) 2.64
Age-related crossover in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst (2008) 2.64
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet (2009) 2.58
MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst (2005) 2.57